Technical Analysis for IMMU - Immunomedics, Inc.

Grade Last Price % Change Price Change
grade C 15.82 2.46% 0.38
IMMU closed down 2.65 percent on Friday, October 18, 2019, on 80 percent of normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical IMMU trend table...

Date Alert Name Type % Chg
200 DMA Support Bullish 2.46%
MACD Bullish Centerline Cross Bullish 2.46%
Overbought Stochastic Strength 2.46%
Stochastic Reached Overbought Strength -0.25%
Overbought Stochastic Strength -0.25%
Up 3 Days in a Row Strength -0.25%
Crossed Above 200 DMA Bullish 3.40%
Crossed Above 20 DMA Bullish 3.40%
Crossed Above 50 DMA Bullish 3.40%
MACD Bullish Signal Line Cross Bullish 3.40%

Older signals for IMMU ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other serious diseases. Its products include epratuzumab, which is in two Phase III clinical trials for the treatment of lupus; Yttrium-90 labeled clivatuzumab tetraxetan, a therapeutic product candidate that completed a Phase Ib clinical trial for the treatment of pancreatic cancer; and Veltuzumab, a humanized anti-CD20 monoclonal antibody for the treatment of non-Hodgkin lymphoma (NHL). The company's products also comprise Milatuzumab, a transmembrane protein that is highly expressed in MM and other B-cell lymphomas and leukemias, and in certain solid tumors; Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled CD22 antibody product candidate for patients with NHL; Labetuzumab, a proprietary humanized antibody, which is in Phase II clinical development stage, targets the carcinoembryonic antigen, CEACAM5; and hRS7, an internalizing humanized anti-epithelial glycoprotein-1 antibody. It also manufactures and commercializes LeukoScan, a diagnostic imaging system to determine the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic foot ulcers. The company has strategic partnerships and relationships with Nycomed GmbH and UCB, S.A.; and a collaboration agreement with Algeta ASA for the development of epratuzumab. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Biotechnology Biopharmaceutical Cancer Immunology Treatment Of Cancer Monoclonal Antibodies Pharmacology Serious Diseases Pancreatic Cancer Humanized Antibody Non Hodgkin Lymphoma Lupus NHL Leukemias Cd20 Milatuzumab Treatment Of Lupus Treatment Of Non Hodgkin Lymphoma Treatment Of Pancreatic Cancer
Is IMMU a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 24.99
52 Week Low 11.55
Average Volume 2,302,011
200-Day Moving Average 15.214
50-Day Moving Average 14.6186
20-Day Moving Average 14.534
10-Day Moving Average 14.611
Average True Range 0.8771
ADX 19.71
+DI 25.6097
-DI 22.037
Chandelier Exit (Long, 3 ATRs ) 14.7987
Chandelier Exit (Short, 3 ATRs ) 14.6813
Upper Bollinger Band 16.4839
Lower Bollinger Band 12.5841
Percent B (%b) 0.73
BandWidth 26.832255
MACD Line 0.0621
MACD Signal Line -0.0921
MACD Histogram 0.1542
Fundamentals Value
Market Cap 1.72 Billion
Num Shares 111 Million
EPS -1.47
Price-to-Earnings (P/E) Ratio -10.50
Price-to-Sales 396.34
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.94
Resistance 3 (R3) 16.91 16.39 16.69
Resistance 2 (R2) 16.39 16.00 16.40 16.61
Resistance 1 (R1) 15.91 15.77 15.65 15.94 16.52
Pivot Point 15.39 15.39 15.26 15.40 15.39
Support 1 (S1) 14.91 15.00 14.65 14.94 14.36
Support 2 (S2) 14.39 14.77 14.40 14.27
Support 3 (S3) 13.91 14.39 14.19
Support 4 (S4) 13.94